Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$89.22 USD
+0.74 (0.84%)
Updated Jun 30, 2022 04:00 PM ET
4-Sell of 5 4
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
LGND 89.22 +0.74(0.84%)
Will LGND be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LGND
Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?
Zacks.com featured highlights include Ligand Pharmaceuticals, Alarm.com Holdings, Radius Global, ADT, Madison Square Garden
LGND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spot the Red Flags & Sell These 5 Toxic Stocks Right Away
Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals
Detoxify Your Holdings by Steering Clear of These 4 Stocks
Other News for LGND
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Ligand initiated with an Outperform at BMO Capital
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
See How Ligand Pharmaceuticals Ranks Among Analysts` Top Picks With Strong Buyback Activity
XOMA: First Steps Towards Greatness